中證網訊 盡管因公(gong)司治(zhi)理問題而帶來(lai)重(zhong)重(zhong)壓力,但科(ke)倫藥業(002422)董事長劉革(ge)新還是以(yi)一種坦(tan)誠的姿態向股東(dong)做出解釋和承諾(nuo)。5月21日,劉革(ge)新在(zai)該公(gong)司2013年度股東(dong)大會(hui)上頻(pin)頻(pin)向股東(dong)道歉,并承諾(nuo)“以(yi)后再也不會(hui)犯同樣的錯誤”。
2013年(nian)(nian),科倫藥(yao)業(ye)因(yin)涉(she)嫌信息披(pi)露(lu)違法違規而被中國證監(jian)會(hui)(hui)(hui)立案調查,引(yin)發(fa)外界對該公司治(zhi)理(li)問(wen)題的擔憂。在當日舉行的年(nian)(nian)度股東大會(hui)(hui)(hui)上,這一問(wen)題再度成為參會(hui)(hui)(hui)小股東關注的焦(jiao)點(dian)。
對此,劉(liu)革新(xin)屢屢表示歉意(yi),他(ta)解釋稱(cheng),公(gong)(gong)司(si)(si)并(bing)無(wu)本意(yi)要隱瞞(man)關聯交易,被監管層關注(zhu)的問題均發生在公(gong)(gong)司(si)(si)上市前夕,屬于歷史(shi)遺留問題,公(gong)(gong)司(si)(si)當時對相(xiang)關法律法規不熟悉,導致(zhi)留下治理隱患(huan)。他(ta)稱(cheng),當時一些公(gong)(gong)司(si)(si)連法人代表都無(wu)法找到(dao),若以上市公(gong)(gong)司(si)(si)為主體貿(mao)然介入(ru),面臨巨(ju)大的未知風險,因(yin)此公(gong)(gong)司(si)(si)被迫采取(qu)了(le)折中方(fang)案,為日后的關聯交易埋下隱患(huan)。“信息披露違(wei)規對我們(men)來說是長(chang)期(qi)教訓,以后我們(men)決不會再(zai)犯同樣(yang)的錯誤。”
對于(yu)未來的發(fa)展,劉(liu)革新(xin)稱,在(zai)抗生素(su)(su)產(chan)業上(shang),公(gong)司(si)一定是做全產(chan)業鏈(lian),“川寧項(xiang)目絕(jue)對不(bu)會讓股(gu)東失(shi)望”,2016年可能真正體現出(chu)公(gong)司(si)“三(san)(san)發(fa)驅(qu)動(dong)(dong)(dong)”中的“一發(fa)”。根據此(ci)前的公(gong)告(gao),“三(san)(san)發(fa)驅(qu)動(dong)(dong)(dong)”是指(zhi)推(tui)動(dong)(dong)(dong)該公(gong)司(si)發(fa)展的三(san)(san)大動(dong)(dong)(dong)力。第(di)(di)一臺(tai)(tai)(tai)發(fa)動(dong)(dong)(dong)機(ji)(ji)是:通過持續的產(chan)業升級和(he)(he)品種結構調整,不(bu)斷鞏固(gu)和(he)(he)強化(hua)包括輸液(ye)在(zai)內的注射劑產(chan)品集群(qun)的總體優勢,繼續保(bao)持科倫在(zai)輸液(ye)領域的絕(jue)對領先(xian)地(di)位(wei);第(di)(di)二(er)臺(tai)(tai)(tai)發(fa)動(dong)(dong)(dong)機(ji)(ji)是:通過對水、煤(mei)炭、農副產(chan)品等(deng)優質(zhi)自(zi)然資源的創(chuang)新(xin)性(xing)開發(fa)和(he)(he)利(li)用(yong),構建(jian)從中間體、原料藥到制劑的抗生素(su)(su)全產(chan)業鏈(lian)競爭(zheng)優勢,最終掌握抗生素(su)(su)的全球話語權;第(di)(di)三(san)(san)臺(tai)(tai)(tai)發(fa)動(dong)(dong)(dong)機(ji)(ji)是:通過研(yan)發(fa)體系的建(jian)設和(he)(he)多元化(hua)的技(ji)術(shu)創(chuang)新(xin),對優秀仿(fang)制藥、創(chuang)新(xin)型小分子藥物(wu)、新(xin)型給藥系統和(he)(he)生物(wu)技(ji)術(shu)藥物(wu)等(deng)高技(ji)術(shu)內涵藥物(wu)進(jin)行研(yan)發(fa),積累企業基業長青的終極驅(qu)動(dong)(dong)(dong)力量(liang)。
“藥(yao)物(wu)研(yan)發是一(yi)個(ge)非常漫長(chang)的過程,我們傾向于充分利用外部資源(yuan),學習輝瑞等制(zhi)藥(yao)巨(ju)頭,借助(zhu)外部研(yan)發力量攻關”,科倫(lun)藥(yao)業副總(zong)經理、科倫(lun)研(yan)究(jiu)院(yuan)院(yuan)長(chang)、科倫(lun)藥(yao)業首(shou)(shou)席科學家(jia)王晶翼(yi)說,他(ta)們“會(hui)用錢換(huan)時間,但不會(hui)亂花錢”。財報顯(xian)(xian)示,在(zai)藥(yao)物(wu)開(kai)發方面,2013年,科倫(lun)藥(yao)業投入研(yan)發資金超(chao)過4億(yi)元,較上(shang)年同期增長(chang)約99.74%,在(zai)研(yan)產(chan)品有A類(lei)項(xiang)目(mu)155個(ge)(其(qi)中有48個(ge)超(chao)A類(lei)項(xiang)目(mu)),共(gong)立項(xiang)111項(xiang),項(xiang)目(mu)包括(kuo)創新(xin)藥(yao)、高端輸液、雙室(shi)袋及三室(shi)袋系列、品牌仿制(zhi)藥(yao)、新(xin)型給(gei)藥(yao)系統等。2013年,該(gai)公(gong)司共(gong)有有14個(ge)3.1類(lei)新(xin)藥(yao)為國內首(shou)(shou)家(jia)注冊申報,具有國內首(shou)(shou)家(jia)上(shang)市的機會(hui),公(gong)司在(zai)腫瘤靶向藥(yao)物(wu)研(yan)發方面也(ye)取得了顯(xian)(xian)著的進展。
對于公(gong)(gong)司目前(qian)的市(shi)(shi)場表現(xian),劉(liu)革新沒有(you)正面回答,但他建(jian)議,股(gu)(gu)東可以(yi)去比(bi)(bi)較下(xia)同(tong)行(xing)業可比(bi)(bi)公(gong)(gong)司,看(kan)(kan)看(kan)(kan)科倫是否(fou)被低(di)估。4月(yue)(yue)26日,科倫藥業發布公(gong)(gong)告(gao)稱(cheng),劉(liu)革新先生基于對目前(qian)資本(ben)市(shi)(shi)場形勢的認識(shi)及對公(gong)(gong)司未來持續穩定(ding)發展的強烈信心,計劃以(yi)自籌資金(jin)在未來 3 個月(yue)(yue)內根據中國(guo)證(zheng)監會和深圳證(zheng)券交易所(suo)的有(you)關規定(ding)以(yi)及市(shi)(shi)場情況(kuang),增持不(bu)低(di)于公(gong)(gong)司總股(gu)(gu)本(ben) 0.25%且不(bu)超過公(gong)(gong)司總股(gu)(gu)本(ben) 0.50%的股(gu)(gu)份。增持期(qi)間:2014年5月(yue)(yue)1日至2014年7月(yue)(yue)31日。
中(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)聲明:凡本網(wang)注(zhu)明“來源:中(zhong)(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)報·中(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)”的(de)所有作(zuo)(zuo)品,版權均屬于(yu)中(zhong)(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)報、中(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)。中(zhong)(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)報·中(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)與作(zuo)(zuo)品作(zuo)(zuo)者聯(lian)合(he)聲明,任(ren)何組織未經中(zhong)(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)報、中(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)以及作(zuo)(zuo)者書面授權不(bu)(bu)得轉(zhuan)載(zai)、摘編或利(li)用其它方式使用上述作(zuo)(zuo)品。凡本網(wang)注(zhu)明來源非中(zhong)(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)報·中(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)的(de)作(zuo)(zuo)品,均轉(zhuan)載(zai)自其它媒體,轉(zhuan)載(zai)目的(de)在于(yu)更好服務讀者、傳(chuan)遞信息之需,并不(bu)(bu)代表本網(wang)贊同其觀點,本網(wang)亦不(bu)(bu)對其真(zhen)實(shi)性負責(ze),持異議者應與原出(chu)處(chu)單(dan)位主張權利(li)。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中國證券報社版(ban)權(quan)所有,未(wei)經(jing)書面(mian)授(shou)權(quan)不得(de)復制或建立鏡(jing)像
經營許(xu)可證(zheng)編號:京B2-20180749 京公網(wang)安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved